Ryan Specialty Downgraded to Neutral with $35 Target After Legal Probe and Revenue Drop
RYAN•Goldman Sachs cut Ryan Specialty to Neutral with a $35.00 price target after Q4 2025 organic revenue growth plunged and EBITDAC margin declined. The company faces a securities-law probe as rate cuts of 25–35% and intensifying pricing pressure weighed on results before a $300 million share buyback boost.
1. Goldman Sachs Downgrades to Neutral
Goldman Sachs downgraded Ryan Specialty from Buy to Neutral and set a $35.00 price target after evaluating its fourth-quarter performance. The stock was trading near $32.56 at the time of the revision.
2. Q4 2025 Revenue and Margin Pressures
Ryan Specialty reported sharply lower organic revenue growth and a decline in EBITDAC margin in Q4 2025, driven by rate decreases of 25–35% and intensifying difficult pricing trends across its portfolio.
3. Legal Probe and Compliance Risks
The company is under a securities-law investigation prompted by its weakened revenue growth and margin compression in the fourth quarter, raising potential compliance and litigation risks.
4. Share Buyback Program and Credit Ratings
Ryan Specialty’s board increased its share repurchase authorization by $300 million after deploying $260 million, while its Singapore unit and eight affiliates retained exceptional PA-1 underwriting assessments.
